Products
MOSQUIRON®
An Extended Residual Activity Formulation of the Insect Growth Regulator Novaluron
for Control of Mosquito and Midge Larvae
Product Attributes:
Non-dust, odour free, requires no mixing
Dispersion throughout the mosquito larval habitats
Available in different shapes and sizes for different larval habitats
Available in packages suitable for Commercial/Professional and Domestic users
Patented Formulation
PROVIDES long lasting activity of novaluron
RESPONSIBLE – an alternate tool to combat resistance to current mosquito larvacides
HIGH POTENCY - reduces the volume of pesticide usage
ENVIRONMENTALLY APPROPRIATE – excellent safety profile
POTABLE WATER – approved for use in drinking water in the United States
ADDITIONAL INFORMATION:
Active Ingredient: novaluron Family: Benzoyl Urea
Mode of Action: Chitin Synthesis Inhibitor
HISTORY:
In 2004 WHO published a report with the following CONCLUSIONS:
1. "Given its considerable activity against all developmental stages of mosquitoes, novaluron offers the flexibility of timing of application against asynchronous broods."
2. "Field studies in artificial and natural habitats showed that novaluron 10EC was effective against populations of Ae. aegypti (Mexico and Thailand)
, Anopheles species (Mexico and Sri Lanka) and Culex species (India, Mexico and the United States) at application rates of 10-50 ppb."
3. "Studies on the efficacy of this formulation in water-storage containers against Ae. aegypti provided long-lasting residual activity for 5-6 months."
4. "Similarly, in confined sources of larvae such as gem pits and disused wells, novaluron at practical dosages provided control for up to 4 months."
In that same report WHO, stated the following:
RECOMMENDATIONS:
1. The use of novaluron larvacide for application in temporary mosquito habitats, polluted water and non-drinking water-storage containers at 10-50 ppb a.i. The higher dosages are needed for polluted and vegetated habitats.
2. Although the 10EC formulation of novaluron has been found to show a high level of activity against larvae of various of mosquitoes, there is a critical need for the development and evaluation of other formulations (e.g. tablets and granules) operational suitable for use in specific larval habitats such as containers and other confined sources of larvae.
3. WHO should conduct an assessment of the safety of novaluron for use in drinking water as a mosquito larvacide.
In 2007 WHO recommended novaluron for use in drinking water.
ADDITIONAL ATTRIBUTES OF THE MOSQUIRON FORMULATIONS:
1. Addresses "the critical need for the development and evaluation of other formulations (e.g. granules and tablets) operationally suitable for use in specific larval habitats such as containers and other confined sources of larvae."
2. Registered for drinking water by the E.P.A. in the United States.
3. Increased the solubility of novaluron in water from 3 to 15 ppb versus the WHO Report, "Field studies in artificial and natural habitats showed that novaluron 10EC was effective...at application rates of 10-50 ppb."
4. Increased residual activity in excess of six months regardless of polluting organic matter at 3-15 ppb versus the WHO Report, "50 ppb a.i. dosages are needed for polluted and vegetated habitats."
These new properties are attributed to the formulations' novel carrier technology (involving food grade inerts) which has been patented in numerous countries.
LOCATIONS OF RESEARCH TRIALS SUPPORTING FEDERAL REGISTRATIONS IN THE U.S. AND CANADA
Abbottsford, British Columbia, Canada; Marshall, Wisconsin, U.S.; Meansville, Georgia, U.S.; Panama City, Florida, U.S.; Poratge La Prairie, Manitoba, Canada.
LOCATIONS OF TRIALS SUPPORTING MARKETING IN 2013
Brazil, California, Florida, Malaysia, Manitoba, Michigan, Texas, Utah and Vietnam.
MOSQUIRON IS CURRENTLY REGISTERED FOR SALE IN THE FOLLOWING U.S. STATES
Alabama, Colorado, Delaware, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Ohio, South Dakota, Texas, Utah and Wyoming.
Please use the Tumaini link for additional information.
VectoBac® and VectoLex®
Pestalto is a distributor for the VectoBac and VectoLex product lines in Ontario, Canada.
VectoBac contains the naturally occurring mosquito and black fly larval pathogen, Bacillus thuringiensis israeliensis. Dr. Tyler contributed to the product development and introduction of VectoBac products for mosquito and black fly control in Canada in the late 1980's.
VectoLex has the active ingredient, Bacillus sphaericus, and was more recently registered for the Canadian market.
Curtis DYNA-FOG®
Pestalto is the Canadian distributor and maintenance representative for Dyna-Fog's full range of mosquito ULV and fogging equipment which include hand-held, back pack and vehicle mounted models. Please see the link for additional information.
Download: Tumaini/Mosquiron PDF
® MOSQUIRON is a Registered Trademark of Makhteshim Chemical Works Ltd
® Vectobac and VectoLex are Registered Tradenames of Valent Biosciences Corporation.
MOSQUIRON®
MOSQUIRON®
An Extended Residual Activity Formulation of the Insect Growth Regulator Novaluron
for Control of Mosquito and Midge Larvae
Product Attributes:
Non-dust, odour free, requires no mixing
Dispersion throughout the mosquito larval habitats
Available in different shapes and sizes for different larval habitats
Available in packages suitable for Commercial/Professional and Domestic users
Patented Formulation
Non-dust, odour free, requires no mixing
Dispersion throughout the mosquito larval habitats
Available in different shapes and sizes for different larval habitats
Available in packages suitable for Commercial/Professional and Domestic users
Patented Formulation
PROVIDES long lasting activity of novaluron
RESPONSIBLE – an alternate tool to combat resistance to current mosquito larvacides
HIGH POTENCY - reduces the volume of pesticide usage
ENVIRONMENTALLY APPROPRIATE – excellent safety profile
POTABLE WATER – approved for use in drinking water in the United States
ADDITIONAL INFORMATION:
Active Ingredient: novaluron Family: Benzoyl Urea
Mode of Action: Chitin Synthesis Inhibitor
HISTORY:
In 2004 WHO published a report with the following CONCLUSIONS:
In 2004 WHO published a report with the following CONCLUSIONS:
1. "Given its considerable activity against all developmental stages of mosquitoes, novaluron offers the flexibility of timing of application against asynchronous broods."
2. "Field studies in artificial and natural habitats showed that novaluron 10EC was effective against populations of Ae. aegypti (Mexico and Thailand)
, Anopheles species (Mexico and Sri Lanka) and Culex species (India, Mexico and the United States) at application rates of 10-50 ppb."
3. "Studies on the efficacy of this formulation in water-storage containers against Ae. aegypti provided long-lasting residual activity for 5-6 months."
4. "Similarly, in confined sources of larvae such as gem pits and disused wells, novaluron at practical dosages provided control for up to 4 months."
In that same report WHO, stated the following:
RECOMMENDATIONS:
In that same report WHO, stated the following:
RECOMMENDATIONS:
1. The use of novaluron larvacide for application in temporary mosquito habitats, polluted water and non-drinking water-storage containers at 10-50 ppb a.i. The higher dosages are needed for polluted and vegetated habitats.
2. Although the 10EC formulation of novaluron has been found to show a high level of activity against larvae of various of mosquitoes, there is a critical need for the development and evaluation of other formulations (e.g. tablets and granules) operational suitable for use in specific larval habitats such as containers and other confined sources of larvae.
3. WHO should conduct an assessment of the safety of novaluron for use in drinking water as a mosquito larvacide.
In 2007 WHO recommended novaluron for use in drinking water.
In 2007 WHO recommended novaluron for use in drinking water.
ADDITIONAL ATTRIBUTES OF THE MOSQUIRON FORMULATIONS:
1. Addresses "the critical need for the development and evaluation of other formulations (e.g. granules and tablets) operationally suitable for use in specific larval habitats such as containers and other confined sources of larvae."
2. Registered for drinking water by the E.P.A. in the United States.
3. Increased the solubility of novaluron in water from 3 to 15 ppb versus the WHO Report, "Field studies in artificial and natural habitats showed that novaluron 10EC was effective...at application rates of 10-50 ppb."
4. Increased residual activity in excess of six months regardless of polluting organic matter at 3-15 ppb versus the WHO Report, "50 ppb a.i. dosages are needed for polluted and vegetated habitats."
These new properties are attributed to the formulations' novel carrier technology (involving food grade inerts) which has been patented in numerous countries.
LOCATIONS OF RESEARCH TRIALS SUPPORTING FEDERAL REGISTRATIONS IN THE U.S. AND CANADA
Abbottsford, British Columbia, Canada; Marshall, Wisconsin, U.S.; Meansville, Georgia, U.S.; Panama City, Florida, U.S.; Poratge La Prairie, Manitoba, Canada.
Abbottsford, British Columbia, Canada; Marshall, Wisconsin, U.S.; Meansville, Georgia, U.S.; Panama City, Florida, U.S.; Poratge La Prairie, Manitoba, Canada.
LOCATIONS OF TRIALS SUPPORTING MARKETING IN 2013
Brazil, California, Florida, Malaysia, Manitoba, Michigan, Texas, Utah and Vietnam.
Brazil, California, Florida, Malaysia, Manitoba, Michigan, Texas, Utah and Vietnam.
MOSQUIRON IS CURRENTLY REGISTERED FOR SALE IN THE FOLLOWING U.S. STATES
Alabama, Colorado, Delaware, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Ohio, South Dakota, Texas, Utah and Wyoming.
Alabama, Colorado, Delaware, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Ohio, South Dakota, Texas, Utah and Wyoming.
Please use the Tumaini link for additional information.
VectoBac® and VectoLex®
VectoBac® and VectoLex®
Pestalto is a distributor for the VectoBac and VectoLex product lines in Ontario, Canada.
VectoBac contains the naturally occurring mosquito and black fly larval pathogen, Bacillus thuringiensis israeliensis. Dr. Tyler contributed to the product development and introduction of VectoBac products for mosquito and black fly control in Canada in the late 1980's.
VectoLex has the active ingredient, Bacillus sphaericus, and was more recently registered for the Canadian market.
Curtis DYNA-FOG®
Pestalto is the Canadian distributor and maintenance representative for Dyna-Fog's full range of mosquito ULV and fogging equipment which include hand-held, back pack and vehicle mounted models. Please see the link for additional information.
Download: Tumaini/Mosquiron PDF
® MOSQUIRON is a Registered Trademark of Makhteshim Chemical Works Ltd
® Vectobac and VectoLex are Registered Tradenames of Valent Biosciences Corporation.
® MOSQUIRON is a Registered Trademark of Makhteshim Chemical Works Ltd
® Vectobac and VectoLex are Registered Tradenames of Valent Biosciences Corporation.
Click here to visit www.tumaini.ca
Click here to visit www.dynafogcanada.ca